<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02518737</url>
  </required_header>
  <id_info>
    <org_study_id>GRD</org_study_id>
    <nct_id>NCT02518737</nct_id>
  </id_info>
  <brief_title>Examination of the Postprandial Bone Remodeling in Persons With Reduced GIP-Receptor Activity</brief_title>
  <official_title>Examination of the Postprandial Bone Remodeling in Persons With Reduced Activity of the Receptor for the Enteric Hormone Glucose-dependent Insulinotropic Polypeptide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Glostrup University Hospital, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Novo Nordisk Foundation Center for Basic Metabolic Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Copenhagen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The bone tissue of the human adult body is in a constant process of break-down (resorption)
      and rebuilding (formation), a process called bone remodeling. The extent to which bone
      remodeling happens varies during the day, especially a decrease in the bone resorption is
      observed after eating.

      The overall purpose of this study is to examine the possible role of the hormone
      Glucose-dependent Insulinotropic Polypeptide (GIP) in Bone Remodeling. GIP is released from
      cells in the gut after eating, and previous studies have shown an effect of GIP on bone
      tissue. In addition, it has been observed that the risk of bone fracture is 60% higher in
      women with a mutation in the GIP receptor, when compared to women with a normal functioning
      GIP receptor.

      In the present study humans with a mutation in their GIP receptor is compared to humans with
      a normal functioning GIP receptor. The study population will be examined during a meal
      stimulation test, where blood will be sampled regularly. The blood samples will be examined
      for markers of bone resorption among other markers of bone remodeling, GIP and other gut
      hormones.

      The hypothesis for the present study is that GIP secreted after meal ingestion inhibits bone
      resorption. Thus it is expected that the decrease in resorption is less pronounced in the
      humans carrying the GIP-receptor mutation, compared to humans with a normal functioning GIP
      receptor.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>CTx</measure>
    <time_frame>7, 15, 30, 45, 60, 90, 120, 150, 180, 240 minutes after intake of the meal test.</time_frame>
    <description>CTx is a biomarker of bone resorption.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">36</enrollment>
  <condition>Bone Remodeling</condition>
  <arm_group>
    <arm_group_label>GIP-receptor deficient</arm_group_label>
    <description>Persons with a mutation (Glu354Gln) causing their GIP-receptor to loose function.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <description>Matched controls, with a normal functioning GIP-receptor.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Meal Test</intervention_name>
    <arm_group_label>GIP-receptor deficient</arm_group_label>
    <arm_group_label>Controls</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The groups will be recruited from the Helbred2006 cohort, Glostrup Hospital, Denmark.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Verified mutation (Glu354Gln) of the GIP-receptor

        Exclusion Criteria:

          -  Type 2 diabetes

          -  Pregnancy

          -  Previous long-lasting treatment with steroids

          -  On-going steroid treatment (with the exception of inhalation-steroids)

          -  Osteoporosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bolette Hartmann, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Copenhagen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Biomedical Sciences, University of Copenhagen</name>
      <address>
        <city>Copenhagen</city>
        <zip>2200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <reference>
    <citation>Qvist P, Christgau S, Pedersen BJ, Schlemmer A, Christiansen C. Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting. Bone. 2002 Jul;31(1):57-61.</citation>
    <PMID>12110413</PMID>
  </reference>
  <reference>
    <citation>Nielsen HK, Brixen K, Kassem M, Christensen SE, Mosekilde L. Diurnal rhythm in serum osteocalcin: relation with sleep, growth hormone, and PTH(1-84). Calcif Tissue Int. 1991 Dec;49(6):373-7.</citation>
    <PMID>1818760</PMID>
  </reference>
  <reference>
    <citation>Nissen A, Christensen M, Knop FK, Vilsbøll T, Holst JJ, Hartmann B. Glucose-dependent insulinotropic polypeptide inhibits bone resorption in humans. J Clin Endocrinol Metab. 2014 Nov;99(11):E2325-9. doi: 10.1210/jc.2014-2547. Epub 2014 Aug 21.</citation>
    <PMID>25144635</PMID>
  </reference>
  <reference>
    <citation>Torekov SS, Harsløf T, Rejnmark L, Eiken P, Jensen JB, Herman AP, Hansen T, Pedersen O, Holst JJ, Langdahl BL. A functional amino acid substitution in the glucose-dependent insulinotropic polypeptide receptor (GIPR) gene is associated with lower bone mineral density and increased fracture risk. J Clin Endocrinol Metab. 2014 Apr;99(4):E729-33. doi: 10.1210/jc.2013-3766. Epub 2014 Jan 21.</citation>
    <PMID>24446656</PMID>
  </reference>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 5, 2015</study_first_submitted>
  <study_first_submitted_qc>August 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2015</study_first_posted>
  <last_update_submitted>July 27, 2016</last_update_submitted>
  <last_update_submitted_qc>July 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Copenhagen</investigator_affiliation>
    <investigator_full_name>Bolette Hartmann</investigator_full_name>
    <investigator_title>PhD, Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Glucose-dependent Insulinotropic Polypeptide</keyword>
  <keyword>Receptor Deficiency</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastric Inhibitory Polypeptide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

